Nicotine regulates SH-SY5Y neuroblastoma cell proliferation through the release of brain-derived neurotrophic factor

Brain Research

Volumn 1101, Issue 1, 2006, Pages 36-42

  Serres, Florence ^a,b   Carney, Stephen L ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

BDNF; Growth factor; Mecamylamine; Methyllycaconitine; Nicotine; TrkB

Indexed keywords

AR 17779; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; K 252A; MECAMYLAMINE; METHYLLYCACONITINE; NEUTRALIZING ANTIBODY; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR ANTIBODY; RETINOIC ACID; SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,5' OXAZOLIDIN 2' ONE]; UNCLASSIFIED DRUG;

ARTICLE; CELL DENSITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN SECRETION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ACONITINE; ANTIBODIES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CARBAZOLES; CARBON ISOTOPES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MECAMYLAMINE; NEUROBLASTOMA; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; RECEPTOR, TRKB; THYMIDINE; TIME FACTORS;

EID: 33745937107     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.05.023     Document Type: Article

References (39)

1. Alves G., Kurz M., Lie S.A., and Larsen J.P. Cigarette smoking in Parkinson's disease: influence on disease progression. Mov. Disord. 19 (2004) 1087-1092
2. Balkowiec A., and Katz D.M. Cellular mechanisms regulating activity-dependent release of native brain-derived neurotrophic factor from hippocampal neurons. J. Neurosci. 22 (2002) 10399-10407
3. Buisson B., and Bertrand D. Chronic exposure to nicotine upregulates the human (alpha)4(beta)2 nicotinic acetylcholine receptor function. J. Neurosci. 21 (2001) 1819-1829
4. Edsjo A., Lavenius E., Nilsson H., Hoehner J.C., Simonsson P., Culp L.A., Martinsson T., Larsson C., and Pahlman S. Expression of trkB in human neuroblastoma in relation to MYCN expression and retinoic acid treatment. Lab. Invest. 83 (2003) 813-823
5. Ferrer I., Marin C., Rey M.J., Ribalta T., Goutan E., Blanco R., Tolosa E., and Marti E. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J. Neuropathol. Exp. Neurol. 58 (1999) 729-739
6. Finkbeiner S. Calcium regulation of the brain-derived neurotrophic factor gene. Cell. Mol. Life Sci. 57 (2000) 394-401
7. French S.J., Humby T., Horner C.H., Sofroniew M.V., and Rattray M. Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine. Brain Res. Mol. Brain Res. 67 (1999) 124-136
8. Gould J., Reeve H.L., Vaughan P.F., and Peers C. Nicotinic acetylcholine receptors in human neuroblastoma (SH-SY5Y) cells. Neurosci. Lett. 145 (1992) 201-204
9. Guan Z.Z., Yu W.F., and Nordberg A. Dual effects of nicotine on oxidative stress and neuroprotection in PC12 cells. Neurochem. Int. 43 (2003) 243-249
10. Halvorsen S.W., Jiang N., and Malek R. Regulation of nicotinic acetylcholine receptors on human neuroblastoma cells during differentiation. Biochem. Pharmacol. 50 (1995) 1665-1671
11. Hsu Y.N., Amin J., Weiss D.S., and Wecker L. Sustained nicotine exposure differentially affects alpha 3 beta 2 and alpha 4 beta 2 neuronal nicotinic receptors expressed in Xenopus oocytes. J. Neurochem. 66 (1996) 667-675
12. Kaplan D.R., Matsumoto K., Lucarelli E., and Thiele C.J. Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells, Eukaryotic Signal Transduction Group. Neuron 11 (1993) 321-331
13. Ksir C., Hakan R.L., and Kellar K.J. Chronic nicotine and locomotor activity: influences of exposure dose and test dose. Psychopharmacology (Berlin) 92 (1987) 25-29
14. Lemay S., Blanchet P., Chouinard S., Masson H., Soland V., and Bedard M.A. Poor tolerability of a transdermal nicotine treatment in Parkinson's disease. Clin. Neuropharmacol. 26 (2003) 227-229
15. Lemay S., Chouinard S., Blanchet P., Masson H., Soland V., Beuter A., and Bedard M.A. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 31-39
16. Lucarelli E., Kaplan D., Matsumoto K., Sickafuse S., and Thiele C.J. Retinoic acid induced differentiation is mediated by trkB receptors. Prog. Clin. Biol. Res. 385 (1994) 185-198
17. Maggio R., Riva M., Vaglini F., Fornai F., Racagni G., and Corsini G.U. Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism. J. Neural Transm. 104 (1997) 1113-1123
18. Maggio R., Riva M., Vaglini F., Fornai F., Molteni R., Armogida M., Racagni G., and Corsini G.U. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J. Neurochem. 71 (1998) 2439-2446
19. 2+-dependent gene expression. Crit. Rev. Neurobiol. 16 (2004) 43-49
20. Middlemas D.S., Kihl B.K., Zhou J., and Zhu X. Brain-derived neurotrophic factor promotes survival and chemoprotection of human neuroblastoma cells. J. Biol. Chem. 274 (1999) 16451-16460
21. Molinari E.J., Delbono O., Messi M.L., Renganathan M., Arneric S.P., Sullivan J.P., and Gopalakrishnan M. Up-regulation of human alpha7 nicotinic receptors by chronic treatment with activator and antagonist ligands. Eur. J. Pharmacol. 347 (1998) 131-139
22. Mullen G., Napier J., Balestra M., Decory T., Hale G., Macor J., Mack R., Loch J., Wu E., Kover A., Verhoest P., Sampognaro A., Phillips E., Zhu Y., Murray R., Griffith R., Blosser J., Gurley D., Machulskis A., Zongrone J., Rosen A., and Gordon J. (-)-Spiro[1-azabicyclo[2.2.2]octane-3, 5′-oxazolidin-2′-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha7 nicotinic acetylcholine receptor. J. Med. Chem. 43 (2000) 4045-4050
23. Nordberg A., Lundqvist H., Hartvig P., Lilja A., and Langstrom B. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains-in vivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord. 9 (1995) 21-27
24. Olale F., Gerzanich V., Kuryatov A., Wang F., and Lindstrom J. Chronic nicotine exposure differentially affects the function of human alpha3, alpha4, and alpha7 neuronal nicotinic receptor subtypes. J. Pharmacol. Exp. Ther. 283 (1997) 675-683
25. Peng X., Gerzanich V., Anand R., Wang F., and Lindstrom J. Chronic nicotine treatment up-regulates alpha3 and alpha7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y. Mol. Pharmacol. 51 (1997) 776-784
26. Perry E., Martin-Ruiz C., Lee M., Griffiths M., Johnson M., Piggott M., Haroutunian V., Buxbaum J.D., Nasland J., Davis K., Gotti C., Clementi F., Tzartos S., Cohen O., Soreq H., Jaros E., Perry R., Ballard C., McKeith I., and Court J. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur. J. Pharmacol. 393 (2000) 215-222
27. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., Irving D., Brown A., and Perry R.H. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 64 (1995) 385-395
28. Quik M., and Kulak J.M. Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology 23 (2002) 581-594
29. Ridley D.L., Rogers A., and Wonnacott S. Differential effects of chronic drug treatment on alpha3* and alpha7 nicotinic receptor binding sites, in hippocampal neurones and SH-SY5Y cells. Br. J. Pharmacol. 133 (2001) 1286-1295
30. Ridley D.L., Pakkanen J., and Wonnacott S. Effects of chronic drug treatments on increases in intracellular calcium mediated by nicotinic acetylcholine receptors in SH-SY5Y cells. Br. J. Pharmacol. 135 (2002) 1051-1059
31. Ruiz-Leon Y., and Pascual A. Induction of tyrosine kinase receptor b by retinoic acid allows brain-derived neurotrophic factor-induced amyloid precursor protein gene expression in human SH-SY5Y neuroblastoma cells. Neuroscience 120 (2003) 1019-1026
32. Ryan R.E., Ross S.A., Drago J., and Loiacono R.E. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br. J. Pharmacol. 132 (2001) 1650-1656
33. Schulte J.H., Schramm A., Klein-Hitpass L., Klenk M., Wessels H., Hauffa B.P., Eils J., Eils R., Brodeur G.M., Schweigerer L., Havers W., and Eggert A. Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. Oncogene 24 (2005) 165-177
34. Singh A., Potter A., and Newhouse P. Nicotinic acetylcholine receptor system and neuropsychiatric disorders. IDrugs 7 (2004) 1096-1103
35. Sokolova E., Matteoni C., and Nistri A. Desensitization of neuronal nicotinic receptors of human neuroblastoma SH-SY5Y cells during short or long exposure to nicotine. Br. J. Pharmacol. 146 (2005) 1087-1095
36. 2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20 (1998) 709-726
37. Terry Jr. A.V., and Clarke M.S. Nicotine stimulation of nerve growth factor receptor expression. Life Sci. 55 (1994) PL91-PL98
38. Wang F., Gerzanich V., Wells G.B., Anand R., Peng X., Keyser K., and Lindstrom J. Assembly of human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, and beta4 subunits. J. Biol. Chem. 271 (1996) 17656-17665
39. Wang F., Nelson M.E., Kuryatov A., Olale F., Cooper J., Keyser K., and Lindstrom J. Chronic nicotine treatment up-regulates human alpha3 beta2 but not alpha3 beta4 acetylcholine receptors stably transfected in human embryonic kidney cells. J. Biol. Chem. 273 (1998) 28721-28732